The Vaccine Formulation Institute is a not-for-profit company dedicated to the development of adjuvants and formulations, with state-of-the-art laboratories in Switzerland.

VFI was initially created in 2012 with the support of the World Health Organization in order to help the vaccine community to access more easily know-how and expertise in vaccine formulation and adjuvant technologies, in order to catalyzing the development of new-generation adjuvanted vaccines.

VFI’s mission is to develop clinically-relevant adjuvants and vaccine formulations to fight diseases in all parts of the world on an open-access basis. Its main activities consist of research and development of innovative adjuvant technologies, provision of adjuvants to the vaccine community for preclinical and clinical evaluation of vaccines, technology transfer of adjuvant technologies to industry partners to make them broadly accessible and affordable, and provision of training on adjuvants and vaccine formulations to vaccinologists worlwide, with a specific focus on low- and middle-income countries.

VFI has recently completed the development of SWE, the first adjuvant for prophylactic human vaccines in open-access since the aluminium salts. SWE is an oil-in-water emulsion now commercialized by Seppic under the trademark Sepivac SWE^TM which is under clinical evaluation by numerous institutions worldwide.